Trial Search Results

Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

This study will evaluate the safety and efficacy of CTP-543 in adult patients with chronic, moderate to severe alopecia areata.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Concert Pharmaceuticals

Stanford Investigator(s):


  • Drug: CTP-543
  • Drug: Placebo


Phase 2


Inclusion Criteria:

   - Definitive diagnosis of alopecia areata with a current episode lasting at least 6
   months and not exceeding 10 years at the time of Screening. Total disease duration
   greater than 10 years is permitted.

   - At least 50% scalp hair loss, as defined by a SALT score ≥50, at Screening and

   - Clinical lab results within the normal range

Exclusion Criteria:

   - Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical
   treatment to the scalp, significant trauma to the scalp, or untreated actinic
   keratosis on the scalp.

   - Treatment with systemic immunosuppressive medications or biologics.

   - Vaccination with herpes zoster vaccine or any live virus within 6 weeks of screening
   or during the study

Ages Eligible for Study

18 Years - 65 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Michelle Kim